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Abstract
Background:  Obesity causes or exacerbates a host of medical conditions, including
cardiovascular, pulmonary, and endocrine diseases. Recently obesity in elderly women was
associated with greater risk of dementia, white matter ischemic changes, and greater brain atrophy.
The purpose of this study was to determine whether body type affects global brain volume, a
marker of atrophy, in middle-aged men and women.
Methods: T1-weighted 3D volumetric magnetic resonance imaging was used to assess global brain
volume for 114 individuals 40 to 66 years of age (average = 54.2 years; standard deviation = 6.6
years; 43 men and 71 women). Total cerebrospinal fluid and brain volumes were obtained with an
automated tissue segmentation algorithm. A regression model was used to determine the effect of
age, body mass index (BMI), and other cardiovascular risk factors on brain volume and cognition.
Results: Age and BMI were each associated with decreased brain volume. BMI did not predict
cognition in this sample; however elevated diastolic blood pressure was associated with poorer
episodic learning performance.
Conclusion: These findings suggest that middle-aged obese adults may already be experiencing
differentially greater brain atrophy, and may potentially be at greater risk for future cognitive
decline.
Background
The prevalence of overweight and obese people in the
United States and other developed nations has progres-
sively increased over the last twenty years and is now at
epidemic proportions[1]. It is estimated that greater than
60% of all Americans are overweight, and approximately
one-half of that group are classified as obese[2]. Previous
studies have found that obesity reduces life expectancy [3]
by causing or exacerbating various medical conditions
including coronary heart disease (CHD), type 2 diabetes
mellitus, hypertension, obstructive sleep apnea, and
stroke[4]. Neurocognitive health may also be related to
obesity. A recent study determined that obesity was
strongly associated with poorer cognitive function in indi-
viduals over 65 years of age [5]. In a population-based
sample of women aged 70–89 years, greater body mass
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index (BMI) in middle and later life was associated with
cerebral white matter ischemic change [6], a higher inci-
dence of dementia, particularly Alzheimer's disease (AD)
[7], and temporal lobe atrophy [8] in later life.
Brain atrophy involves the loss of tissue volume and is
commonly seen with increasing age [9-11] and neurode-
generative disease[12]. Vascular factors intrinsic to over-
weight individuals, such as hypertension[13,14],
hypercholesterolemia [13,15], endothelial dysfunc-
tion[16,17], and diabetes [18-20] have all been linked to
greater risk for dementia or brain atrophy in the elderly.
Furthermore, older adults with better cardiovascular fit-
ness demonstrate significant improvements in cognitive
function and a significant slowing of age-related atrophy
of gray and white matter[21]. Together these findings sug-
gest that older overweight individuals have a higher risk of
accelerated brain atrophy and concomitant cognitive
decline.
While the deleterious effects of obesity on the brain in the
geriatric population are now apparent, it is not known
whether this relationship occurs in younger persons or is
unique to older populations. This is an important ques-
tion because interventions to reduce the adverse effects of
obesity may have a larger public health impact when
implemented at younger ages. The purpose of the present
study was to determine whether the effect of BMI on brain
atrophy previously observed in elderly females [8] might
also be observable in cognitively healthy adults between
the ages of 40 and 66, and to determine the relationships
between this effect and associated cardiovascular factors
(hypertension and hypercholesterolemia).
Methods
One hundred seventeen participants (44 male, 73 female)
with a mean age of 54.2 years (SD = 6.5) were studied
with magnetic resonance imaging (MRI) and cognitive
testing as part of a cross-sectional study analyzing factors
related to global brain volume and cognition. Sixty-five
participants were recruited from an existing registry
known as the Wisconsin Registry for Alzheimers' Preven-
tion (WRAP)[22] consisting of cognitively normal mid-
dle-aged adults who had at least one parent with AD.
These participants were recruited to enrich the sample
with individuals having risk factors for AD. The remaining
fifty-two participants were recruited somewhat simultane-
ously from the University of Wisconsin-Madison (UWM)
community. This convenience sample was selected to
have no known first-degree family history of AD (with
parents surviving until at least age 70 without dementia).
All participants in this study were required to be between
the ages of 40 and 66 and have no current major Axis I
psychiatric disease or history of major medical conditions
(i.e., traumatic brain injury, neurovascular infarctions,
brain neoplasms or ischemic changes, history of cancer,
diabetes, or condition requiring an invasive brain proce-
dure). Additionally, participants were required to have
normal cognitive function, and MRI scanner compatibil-
ity. Lastly, participants on any medication with potential
to affect cerebral perfusion or cognition (such as beta
blockers, calcium channel antagonists, Angiotensin-con-
verting Enzyme (ACE) inhibitors, statins, or Selective
Serotonin Reuptake Inhibitors (SSRIs)) were excluded
from the analysis.
All participants completed a detailed health history ques-
tionnaire, and were administered a battery of neuropsy-
chological tests and laboratory blood tests. Data were
collected on Apolipoprotein E (APOE) genotype, non-
fasting total blood cholesterol level, blood pressure (BP),
height and weight (for BMI calculation). BP was measured
with the subject seated and at rest using an automated BP
machine. Body height and weight were collected to the
nearest 0.5-inch and one pound respectively. The battery
of neuropsychological tests [23] included the following:
portions of the Wechsler Adult Intelligence Scale-Third
Edition (WAIS-III), the Rey Auditory Verbal Learning Test
(RAVLT), Trail Making Test A and B, and the Center for
Epidemiological Studies Depression (CES-D) Inventory.
All participants gave written informed consent under a
protocol approved by the local institutional review board.
This study was performed in a manner that was in accord-
ance with the Declaration of Helsinki.
Brain imaging
MRI was performed using a General Electric 3.0 Tesla
SIGNA (Waukesha, WI) MRI system. A 3D IR-prepped fast
gradient echo pulse sequence provided high-resolution
T1-weighted structural images. The whole brain was
imaged in the axial plane with the following parameters:
inversion time = 600 ms, fast gradient echo read-out with
TR/TE/flip = 9 ms/1.8 ms/20°; acquisition matrix = 256 ×
192 × 124 (interpolated to 256 × 256 × 124); field of view
= 240 mm; slice thickness = 1.2 mm (124 slices); ± 16 kHz
receiver bandwidth.
A Fast Recovery Fast Spin Echo 2D T2-weighted axial
sequence was also acquired with the same start and stop
locations as the T1 weighted images. The parameters were:
field of view = 240 mm, matrix 256 × 256 × 64, TR = 9000
ms, TE = 93 ms, flip angle = 90. Seventy slices were
acquired; slice thickness = 1.7 mm with 0.3 mm skip. An
experienced neuroradiologist examined all images for evi-
dence of any neurovascular disease or structural abnor-
mality that would exclude the subject from the analysis
(see exclusions above).BMC Neurology 2005, 5:23 http://www.biomedcentral.com/1471-2377/5/23
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Global brain atrophy determination
Global brain volumes, calculated from T1-weighted
images, were analyzed using the cross sectional method of
Structural Image Evaluation, using Normalization, of
Atrophy (SIENAX) within the FSL 3.1β software suite[24].
The SIENAX parameters were set for a three-class segmen-
tation of tissue type and at a 0.3 threshold for segmenting
the brain from extra-axial soft tissue. SIENAX analysis
yielded whole-brain volumetric data, in units of cubic
millimeters, for three different tissue types: cerebral spinal
fluid (CSF), gray matter, and white matter. Total intracra-
nial volume (TICV) was defined as the sum of the three
tissue types, and whole brain parenchyma volume (BV)
was defined as the sum of gray matter and white matter.
BV was divided by TICV to obtain a normalized brain vol-
ume (NBV) with respect to head size.
BMI classification
BMI values were calculated in standard fashion by divid-
ing the weight in kilograms by the square of height in
meters. BMI groups were defined using the World Health
Organization's (WHO) classification system: Under-
weight, less than 18.5; Normal, 18.5–24.9; Overweight,
25.0–29.9; and Obese, greater than 30.0 (in units kg/m2)
[25]. There were not enough underweight participants in
this study group to analyze the effects of underweight on
global brain atrophy. Therefore, individuals classified as
underweight were not included in the statistical analysis.
Statistical analysis
First, Student's t-tests were performed to determine
whether the participants differed by family history of AD
status/referral source. These analyses revealed that UWM
participants were more highly educated than the WRAP
participants, mean = 16.9 (SD = 2.4) and mean = 15.9 (SD
= 2.5) respectively (t [112] = -2.10; p= 0.038). In addition,
the frequency of the APOE ε4 allele was more prevalent in
WRAP participants (54.0 %) compared to the UWM par-
ticipants (13.7 %) (chi-square [1] = 23.5; p < 0.001). No
other variables were found to be significantly different
between the two groups. Nevertheless, 1st degree family
history of AD was treated as an independent variable in
the ensuing stepwise regression model.
Next, linear regression analyses and stepwise regression
analyses were used to predict the effect of BMI, age, non-
fasting total blood cholesterol level, systolic and diastolic
BP, family history of AD, gender, education, and genotype
on the dependent variables of NBV and cognition in sep-
arate analyses. Family history of AD, gender, and APOE
genotype were entered into the model as dichotomous
variables: history/no history of AD, male/female, and
presence/absence of the ε4 allele, respectively. A method
advocated by Baron et al. [26] was used to determine
whether any variable within the stepwise linear regression
model mediated the effect of BMI on NBV.
Three participants were not included in the brain volume
analysis. Two participants were classified as underweight
and one participant was discovered to have a previously
undiagnosed brain tumor. Therefore the final sample size
equaled 114 participants. Nine participants were not
included in the cognition analysis; five participants scored
a fifteen or higher on the CES-D inventory suggesting
symptoms of depression, one participant did not com-
plete the CES-D inventory, and the remaining three partic-
ipants were the same participants excluded in the brain
atrophy analysis (n= 108 participants). Therefore the final
sample size for the cognition analysis equaled 108 partic-
ipants.
Results
One hundred fourteen middle-aged (mean age 54) adults
were administered a comprehensive battery of neuropsy-
chological tests and structural MRI scans in this cross-sec-
tional study examining the brain and cognitive effects
associated with various AD risk factors. Baseline demo-
graphics, cognitive measures, and predictor variables are
shown in Tables 1 and 2.
An initial linear regression analysis examined the effect of
age and BMI on NBV to determine whether the effect
observed in elderly females [8] could be observed in
younger men and women. This analysis indicated that
both age (β = -0.390; t = -4.614; p < 0.0001) and BMI (β =
-0.220; t = -2.605; p = 0.010) were significant predictors of
NBV (R2 = 0.206; F [111, 2] = 14.432; p < 0.00001). Figure
1 shows that elevated BMI is associated with decreased
NBV (after adjusting for age). To determine whether addi-
tional variables may also predict NBV, a stepwise linear
regression analysis was used to examine the effects of age,
BMI, family history of AD, APOE genotype, total choles-
terol, systolic and diastolic BP, and gender on NBV. This
Table 1: Demographic and cognitive measures for men and 
women
Demographic and Cognitive Variables Mean (SD)
Age (years) 54.2 (6.6)
Education (years) 16.4 (2.5)
Classification: n = Normal / Overweight / Obesea 51 / 42 / 21
Trail Making Test B (seconds)b 61.3 (20.2)
WAIS-III-Digit Span raw scoreb 17.9 (3.8)
RAVLT-Total raw scoreb 49.6 (7.9)
CES-Db 4.6 (5.2)
Data are presented as mean (standard deviation).
Notes: aNormal, overweight, and obese body types are defined using 
the World Health Organization's classification system.
bThe cognitive and mood variables are presented for the 108 
participants in the cognitive analysis. Demographic variables are for 
the full sample of 114.BMC Neurology 2005, 5:23 http://www.biomedcentral.com/1471-2377/5/23
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analysis found that age (β = -0.389; t = -4.337; p < 0.001)
and BMI (β = -0.224; t = -2.495; p < 0.014) together were
the best predictors of NBV (R2 = 0.205; F [99, 2] = 12.756;
p < 0.0001). No other variables were significant.
Pearson correlations determined that BMI was signifi-
cantly associated with cholesterol (r = 0.21, p < 0.04) and
systolic BP (r = 0.36, p < 0.001) but was not associated
with any other predictor variable. Neither cholesterol nor
systolic BP were significantly associated with NBV (results
are summarized in Table 2), and therefore did not appear
to mediate the effect of BMI on NBV according to criteria
specified by Baron et al. [26].
Next we applied the same stepwise model above, includ-
ing education to predict the non-crystallized cognitive
abilities of learning, processing speed and working mem-
ory in separate regression models. Age (β = -0.315; t = -
3.417; p < 0.001) and diastolic BP (β = -0.233; t = -2.526;
p = 0.013) were significant predictors of learning (R2 =
0.157; F [101, 2] = 9.252; p < 0.001). Age was the only sig-
nificant predictor of processing speed (R2 = 0.081; F [100,
1] = 8.454; p < 0.01). There was no significant predictor of
working memory in this sample. Average neuropsycho-
logical scores are given in Table 1.
Discussion
This study found that elevated BMI is associated with
reduced brain volumes, suggesting greater global brain
atrophy in middle-aged adults even after adjusting for age.
Episodic learning, working memory, and processing
speed abilities were not associated with BMI in this sam-
ple indicating that the possible effect on cerebral atrophy
had not influenced cognition in participants with a high
BMI. Episodic learning was related to diastolic BP, which
indicates that certain cardiovascular risk factors may be
associated with cognition. However, this finding was iso-
lated to only one of our three categories of cognition. Lon-
gitudinal studies are needed to assess future cognitive
consequences associated with cardiovascular risk factors.
Our finding that BMI affects brain volume at a relatively
young age extends prior research on the harmful effects of
obesity on the brain. We found a 2.4% difference in brain
parenchyma volume for participants classified by the
WHO as obese (n = 21 people; average BMI= 33.3 kg/m2)
compared to participants at a normal, healthy weight (n =
51 people; average BMI = 22.6 kg/m2). Although the mag-
nitude of this difference is not large in this cross-sectional
sample, when we consider these results in the context of
the younger age of our sample (54.2 years), it follows that
obesity in middle age may render an individual more vul-
nerable to brain atrophy over subsequent years, and thus
more vulnerable to cognitive decline or dementia. The
results of this study are consistent with others showing
that life choices (i.e., proper diet, physical activity) may be
neuroprotective and, therefore, potentially reduce the rate
of brain atrophy and concomitant cognitive decline
[27,28]. A longitudinal study of obese people at middle
age is needed to test these hypotheses.
It is unclear through what mechanisms obesity affects
brain volume. Central obesity is associated with risk fac-
tors composing the metabolic syndrome, including high
triglyceride levels, low HDL cholesterol levels, hyperten-
sion, insulin resistance, and prothrombotic and proin-
flammatory states. Prior studies indicate that some of
these risk factors such as mid-life elevations in blood pres-
sure, total cholesterol, and inflammatory markers, are risk
factors for late-life dementia[13,29-31]. In the present
study, neither BP nor non-fasting total cholesterol was
associated with current NBV (though systolic BP did show
a trend). These vascular risk factors may affect chronic cer-
ebral perfusion and β-amyloid generation, thus influenc-
ing neuronal degeneration. Leptin, a peptide related to
obesity, also affects β-amyloid regulation [32]. Further
studies are needed to determine the mechanism by which
BMI affects brain atrophy in middle-aged adults, and
whether this may have future deleterious consequences
on brain structure or function.
Brain tissue is strongly dependent upon oxygen for sur-
vival and is thus vulnerable to hypoxic and ischemic con-
Table 2: Independent associations between each predictor variable and age-adjusted NBV
Regressor Mean (SD) Range β-value p-value
BMI (kg/m2) 26.0 (4.4) (19.0–39.7) -0.22 0.010
Total Cholesterol (mg/dL) 208.0 (37.8) (114–339) -0.12 0.178
Systolic BP (mm Hg) 132.4 (17.2) (102–205) -0.15 0.092
Diastolic BP (mm Hg) 79.4 (10.4) (54–110) -0.09 0.328
Family History AD (y/n) 63/51 0.07 0.448
APOE Genotype (ε4/no ε4) 41/73 -0.04 0.660
Gender (Male/Female) 43/71 0.13 0.137
n = 114. β-values, acquired using individual linear regression analyses with each of the above predictors entered after age, reflect age-adjusted 
predictions of NBV.BMC Neurology 2005, 5:23 http://www.biomedcentral.com/1471-2377/5/23
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ditions. Hypoxia is an inherent consequence of many of
the conditions caused or exacerbated by obesity. Obstruc-
tive sleep apnea[4], CHD [33], asthma [34], and low car-
diovascular fitness[21] may lead to hypoxia which, in
chronic situations, may lead to cognitive decline and neu-
ronal death[35]. Hypoxia is often a consequence of
hypoperfusion, which is strongly associated with
endothelial dysfunction common to individuals with
hypertension, atherosclerosis, and CHD. Endothelial dys-
function, as a result of oxidative stress, may induce neuro-
nal damage and initiate neurodegenerative change[17].
Prevention or postponement of the onset of dementia has
the potential to drastically impact the prevalence of
dementia. The prevalence of AD in the United States alone
is projected to quadruple in the next 50 years, and if dis-
ease onset could be delayed by only one year, it would
result in 800,000 fewer cases[36]. It has been shown that
a person's weight is a reflection of their habitual physical
activity[4]. Given the rapid increase in obesity in the
United States, targeting weight management may signifi-
cantly impact the prevalence of dementia. High dietary fat
intake has been shown to increase the risk of dementia
[37]. Physical fitness significantly improves cognitive
function in older adults[21] and exercise increases the
production of brain-derived neurotrophic factor (BDNF)
and insulin-like growth factor I (IGF-I). BDNF and IGF-I
are neurotrophic hormones that are important for neuro-
genesis, which may protect against neurodegeneration
seen with aging[38]. In older adults the rate of change in
brain volume may be diminished in persons with better
cardiovascular fitness[39].
There were some limitations of this study. First, the range
of BMI was truncated because of the small-bore radius (55
cm) inherent to the MRI scanner. Therefore, participants
in this study could not exceed 260 pounds, which did not
permit an analysis of the effects of extreme obesity. Next,
insulin-dependent diabetic participants were excluded
from this study because diabetes has been shown to be a
risk factor for dementia [18-20] and therefore could be an
important confounder in the analysis. The incidence of
diabetes in our study population was less than 1%, which
was not enough to determine its affect on global brain
volume. Next, the design of this study was cross-sectional
which only allowed for inferences between participants
over a single time point. A longitudinal study is needed to
clarify if the reduced brain volume associated with ele-
vated BMI is representative of a progressive brain atrophy
and concomitant cognitive decline. Additionally, non-
fasting, instead of the more accurate fasting blood choles-
terol values were used as potential predictors of NBV. Fur-
thermore, the BMI measurement itself is only an estimate
of obesity; it does not accurately distinguish fat mass from
lean mass. The highest risk for adverse consequences
related to overweight individuals are best indicated by
excess amounts of adipose tissue, especially that within
the intra-abdominal region. Waist circumference and
skinfold thickness measurements in conjunction with
BMI would have provided a more precise measure of the
amount and location of this excess body fat. Finally, this
study population was self-selected from a group of highly
educated, motivated volunteers; these findings may not
be representative of the general population. However,
these findings are important in understanding how to
potentially target preventive therapies for at-risk individu-
als.
Conclusion
This study found that elevated BMI is associated with
lesser brain volume in middle-aged adults (mean age = 54
years) even after adjusting for age. This study extends prior
research that indicated a similar effect in a population-
based sample of females aged 70 to 84 years with elevated
BMIs from middle age through later life (46 to 84 years).
Further, longitudinal studies are needed to determine
whether the effect we have observed at middle age results
in greater rate of cerebral atrophy over time, and whether
this effect may increase the risk of future cognitive decline
and incidence of dementia.
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